Clinical Trials Directory

Trials / Conditions / Carcinoma, Ovarian Epithelial

Carcinoma, Ovarian Epithelial

14 registered clinical trials studyying Carcinoma, Ovarian Epithelial — 4 currently recruiting.

StatusTrialSponsorPhase
Active Not RecruitingFirst Line Treatment With Olaparib in Combination With Bevacizumab in HRD Positive Patients
NCT06121401
Mario Negri Institute for Pharmacological ResearchPhase 4
Active Not RecruitingAB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Can
NCT05617755
Arsenal Biosciences, Inc.Phase 1
Active Not RecruitingA Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advance
NCT05544929
Novartis PharmaceuticalsPhase 1
RecruitingLetrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer (LEPRE Trial)
NCT05601700
Ente Ospedaliero Ospedali GallieraPhase 3
RecruitingBP1001-A in Patients With Advanced or Recurrent Solid Tumors
NCT04196257
Bio-Path Holdings, Inc.Phase 1
UnknownPembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurre
NCT05158062
Kosei Hasegawa, MD, PhDPhase 2
Active Not RecruitingPembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Can
NCT05116189
Merck Sharp & Dohme LLCPhase 3
Active Not RecruitingAnlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cance
NCT04807166
Wenjun ChengPhase 2
RecruitingPembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer
NCT04519151
Sheba Medical CenterPhase 2
Active Not RecruitingCAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
NCT04660929
Carisma Therapeutics IncPhase 1
UnknownEfficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian
NCT04556071
Xiaoxiang ChenPhase 2
UnknownAnlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer
NCT04566952
Xiaoxiang ChenPhase 2
Active Not RecruitingOregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal De
NCT04498117
CanariaBio Inc.Phase 3
RecruitingDevelopment of a Cinical and Biological Database in Ovarian, Fallopian Tube and Peritoneal Cancers
NCT03976999
Institut du Cancer de Montpellier - Val d'AurelleN/A